Piramal Pharma Solutions’ Grangemouth facility secures updated MHRA GMP certification

Strengthening compliance and global CDMO capabilities  
Piramal Pharma Solutions, part of Piramal Pharma Ltd, announced that its Grangemouth bioconjugates facility has been granted updated MHRA GMP certificates. The certification process followed the submission of a compliance report and a successful desktop inspection by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).  

The Helix building at Grangemouth specializes in clinical and commercial drug substance manufacture and testing, with a focus on bioconjugates. The updated certification ensures the facility continues to meet stringent quality standards, reinforcing Piramal’s position as a trusted global Contract Development and Manufacturing Organization (CDMO).  

Major takeaways 

• Updated MHRA GMP certificates granted to Piramal’s Grangemouth bioconjugates facility  
• Certification covers Helix building, warehouse, and laboratory operations  
• Valid for three years following successful compliance inspection  
• Facility specializes in clinical and commercial drug substance manufacture and testing  
• Strengthens Piramal’s global CDMO capabilities and regulatory trust  

Sources: Yahoo Finance, Newswire, EQS News